An interventional study of Enhanced housing placement assistance and Standard housing placement assistance in HIV/AIDS and Housing Problems, sponsored by New York City Department of Health and Mental Hygiene. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-08.
Sponsored by New York City Department of Health and Mental Hygiene · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Randomized controlled trial of housing placement assistance for homeless persons with HIV
Approximately 800 persons living with HIV/AIDS (PLWHA) reside in HIV emergency single-room-occupancy (SRO) hotels in New York City and do not have the ability to secure permanent housing on their own. The study evaluated a pilot program which fast-tracked PLWHA from HIV emergency SRO hotels into permanent housing. The Enhanced Housing Placement Assistance (EHPA) program had three components: 1) active recruitment of emergency SRO hotel residents with high need for housing; 2) assistance in the rapid (fast-track) acquisition of permanent housing; and 3) participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability. Participants were randomly assigned to either 1) EHPA or 2) usual care, which included standard connections to services and housing programs offered by the New York City HIV/AIDS Services Administration (HASA), Housing Opportunities for Persons With AIDS (HOPWA), or Ryan White services, and were followed over twelve months using a questionnaire developed with significant input from the target population of PLWHA residing in emergency SRO hotels.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
This study's enrollment of 236 is above the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →New York City Department of Health and Mental Hygiene is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Enhanced housing placement assistance
Other: Standard housing placement assistance
assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
Number of Participants With Placement in Permanent Housing
supportive housing, rental assistance, other non-emergency housing, etc.
Time frame: 12 months post-enrollment
Number of Participants With Engagement in HIV Care
any reported HIV viral load (VL) or CD4 test
Time frame: 12 months post-enrollment
Number of Participants With HIV Viral Suppression
Last viral load is under 200 copies/mL
Time frame: 12 months post-enrollment
The study team recruited participants onsite at 22 HIV emergency single adult shelters across NYC between April 2012 and April 2013
| Milestone | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance |
|---|---|---|
| Started | 119 | 117 |
| Completed | 112 | 113 |
| Not completed | 7 | 4 |
supportive housing, rental assistance, other non-emergency housing, etc.
| Participants | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance |
|---|---|---|
| Number of Participants With Placement in Permanent Housing | 53 | 37 |
any reported HIV viral load (VL) or CD4 test
| Participants | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance |
|---|---|---|
| Number of Participants With Engagement in HIV Care | 109 | 110 |
Last viral load is under 200 copies/mL
| Participants | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance |
|---|---|---|
| Number of Participants With HIV Viral Suppression | 53 | 64 |
Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enhanced Housing Placement Assistance | 6/119 (5%) | 0/119 (0%) | 0/119 (0%) |
| Standard Housing Placement Assistance | 4/117 (3.4%) | 0/117 (0%) | 0/117 (0%) |
| Age, Continuous(years) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| Median | 48 (42 to 54) | 48 (40 to 54) | 48 (41.5 to 54) |
| Sex/Gender, Customized(Participants) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| Male | 84 | 90 | 174 |
| Female | 30 | 21 | 51 |
| Transgender | 5 | 6 | 11 |
| Race/Ethnicity, Customized(Participants) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| Non-Hispanic Black | 72 | 70 | 142 |
| Hispanic | 41 | 37 | 78 |
| Non-Hispanic White | 5 | 10 | 15 |
| Unknown | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| United States | 119 | 117 | 236 |
| Placement in Permanent Housing(Participants) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| Count of participants | 0 | 0 | 0 |
| Engagement in HIV Care(Participants) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| Count of participants | 116 | 117 | 233 |
| HIV Viral Suppression(Participants) | Enhanced Housing Placement Assistance | Standard Housing Placement Assistance | Total |
|---|---|---|---|
| Count of participants | 33 | 61 | 94 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2012 to primary completion in Jul 2017, 63 months.
Results were first posted in Feb 2019, 1 year 6 months after primary completion.
Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 63 months is above that.
Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
New York City Department of Health and Mental Hygiene